Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.
The present study, carried out in 16 parkinsonian patients, indicates that L-prolyl-L-leucyl-glycine amide possesses some antiparkinsonian activity and that, if used with levodopa, it can reduce some of the drug-induced dyskinesias. These preliminary observations should be submitted to a controlled trial in a large number of patients before therapeutic applications are claimed.
D000284:Administration, Oral; D000368:Aged; D000577:Amides / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005998:Glycine; D006801:Humans; D007275:Injections, Intravenous; D007930:Leucine; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011392:Proline
D000577:Amides; D000978:Antiparkinson Agents; D010455:Peptides; D004295:Dihydroxyphenylalanine; D011392:Proline; D007930:Leucine; D005998:Glycine